The genetic variability of a tumour could be a predictor for its aggressiveness: the greater the variability in gene expression, the more aggressive the tumour is likely to be. This is the hypothesis that the CNIO Structural Biology and Biocomputing Programme, led by Alfonso Valencia, is testing, after their findings on chronic lymphocytic leukaemia (CLL), now published in the journal Genome Medicine.
This is a grid of proteins conferring aggressiveness in CLL (in consistence with the study).
Credit:Simone Ecker. CNIO
The study has been funded by the Ministry of Economy and Competitiveness, the BLUEPRINT Consortium and the Spanish chronic lymphocytic leukaemia project of the International Cancer Genome Consortium (ICGC).
Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia. Simone Ecker, Vera Pancaldi, Daniel Rico, Alfonso Valencia. Genome Medicine (2015). doi: 10.1186/s13073-014-0125-z